HALO Halozyme Therapeutics, Inc.
Healthcare$68.72+0.59%ClosedMarket Cap: $8.15B
As of 2026-05-26
Valuation
P/E (TTM)
25.26
PEG
—
P/B
36.75
P/S
5.37
EV/EBITDA
10.35
DCF Value
$159.21
FCF Yield
8.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.9%
Operating Margin
57.0%
Net Margin
23.1%
ROE
126.3%
ROA
13.1%
ROIC
23.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $376.7M | 71.1% | $184.5M | $150.0M | $— | — |
| Q4 null | $451.8M | 77.4% | $254.4M | $-141.6M | $— | — |
| FY null | $1.40B | 78.1% | $816.3M | $316.9M | $— | — |
| Q3 null | $354.3M | 79.4% | $217.9M | $175.2M | $— | — |
| Q2 null | $325.7M | 80.3% | $202.4M | $165.2M | $— | — |
| Q1 null | $264.9M | 75.0% | $141.5M | $118.1M | $— | — |
| Q4 null | $298.0M | 85.9% | $175.5M | $137.0M | $— | — |
| FY null | $1.02B | 84.3% | $551.5M | $444.1M | $— | — |
| Q3 null | $290.1M | 83.0% | $163.2M | $137.0M | $— | — |
| Q2 null | $231.4M | 75.2% | $117.2M | $93.2M | $— | — |
| Q1 null | $195.9M | 76.5% | $95.5M | $76.8M | $— | — |
| Q4 2023 | $230.0M | 77.3% | $101.0M | $85.4M | $0.65 | — |